Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With HIV-1: Results Through Week 144 From the Phase 3, Non-inferiority TANGO Randomized Trial
出版年份 2022 全文链接
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now